RetiredUnitedHealthcarePolicy CS079LA.M

Endoscopic therapies for esophageal and gastric motility disorders (POEM, G-POEM, endoluminal GERD therapies)

Coverage determinations for POEM, G-POEM, FLIP testing, and various endoscopic/endoluminal therapies for GERD and related motility disorders for UnitedHealthcare members in Louisiana.

Policy Summary

PayerUnitedHealthcare

PolicyEndoscopic therapies for esophageal and gastric motility disorders (POEM, G-POEM, endoluminal GERD therapies)

Policy CodePolicy CS079LA.M

Change TypeClarified covered vs unproven indicationsreferences updatedpolicy retirement for LA

Effective DateMar 1, 2025

Next Review DateN/A

Key ActionSubmit prior authorization documenting diagnosis of Achalasia or Diffuse Esophageal Spasm and required objective testing when requesting POEM; other indications may be denied.

SourceLink

POLICY UPDATE CHANGES

Added language clarifying that POEM is proven and medically necessary for Achalasia or Diffuse Esophageal Spasm, and unproven and not medically necessary for other indications (e.g., Zenker's diverticula).

Updated Clinical Evidence and References sections to reflect the most current information.

Policy retired for Louisiana membership effective 04/01/2026.

03/01/2025substantive clarification date

04/01/2026retirement date (LA)

Achalasia, DESproven indications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

G-POEMunproven - G-POEM

Z-POEMunproven - Z-POEM

Coverage Criteria and Clinical Determinations

POEM (peroral endoscopic myotomy) — Initial coverage criteria

Covered when ALL of the following are met for POEM:

Indication: Patient has a diagnosis of Achalasia OR Diffuse Esophageal Spasm

POEM is described as proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm.

Evidence Base: Clinical evidence (randomized trials and systematic reviews) demonstrates POEM has comparable short- to intermediate-term efficacy to laparoscopic Heller myotomy for achalasia (non-inferiority shown in RCT) and supportive systematic reviews/meta-analyses exist.

Werner et al. RCT (non-inferiority) and systematic reviews support comparable outcomes.

Provider Qualifications: Procedure performed by a physician with formal POEM training and expertise in submucosal endoscopy and management of adverse events

POEM requires advanced endoscopic skills and formal training to perform safely.

Not Medically Necessary / Unproven Procedures

Not covered / Not medically necessary:

POEM other indications: POEM for indications other than Achalasia or Diffuse Esophageal Spasm (for example, Zenker's diverticula/Z-POEM) is unproven and not medically necessary

Policy explicitly states POEM unproven for other indications due to insufficient evidence of efficacy.

G-POEM: Gastric POEM (G-POEM) for treatment of gastroparesis is unproven and not medically necessary

Policy states G-POEM is unproven/not medically necessary for gastroparesis.

EndoFLIP/FLIP: Endoluminal functional lumen imaging probe (EndoFLIP/FLIP) technology is unproven and not medically necessary for diagnosing Achalasia

Policy states FLIP is unproven for diagnosing achalasia.

Endoluminal GERD therapies and devices:

G-POEM — typical study eligibility

Evidence summary and typical eligibility concepts observed in the literature

G-POEM candidate profile: Patients with severe or refractory gastroparesis (symptoms > 6 months) who have failed dietary modification and optimized medical/prokinetic therapy, with objective assessment such as elevated Gastroparesis Cardinal Symptom Index (GCSI) and abnormal gastric emptying study (GES)GCSI > 2.3 or symptom duration > 6 months

Derived from RCT and cohort eligibility criteria described in the literature.

Z-POEM — comparative effectiveness

Zenker's diverticulum endoscopic approaches evidence summary

Comparative effectiveness summary: Cohort and case-series evidence report comparable initial clinical success for Z-POEM and flexible/rigid endoscopic septotomy but with variable recurrence and adverse event rates; long-term comparative data are limited and prospective studies are recommendedclinical success endpoints vary (e.g., Dakkak and Bennett dysphagia score ≤1)

Available multicenter cohorts and systematic reviews call for prospective comparative studies with longer follow-up.

Stretta — efficacy and uncertainty

Stretta radiofrequency therapy evidence balance

Stretta evidence summary: Randomized and observational studies yield mixed results: some sham-controlled RCTs found no benefit versus sham, while meta-analyses driven by cohort studies suggest improvements in symptom scores and reduced PPI use; overall evidence quality is low-to-uncertain and long-term comparative effectiveness versus laparoscopic fundoplication is not establishedmixed (some RCTs negative; meta-analyses positive driven by observational data)

Systematic reviews and RCTs provide conflicting findings and evidence limitations.

Study-based eligibility constructs

Studies generally enrolled patients meeting ALL of the following features:

Typical study enrollment criteria: Chronic GERD symptoms; prior PPI therapy or PPI dependence (often ≥ 6 months); objective evidence of pathologic esophageal acid exposure or abnormal DeMeester score; limited hiatal hernia size for some devices (for example, <2 cm for GERDx; 2–5 cm included in some EsophyX studies); adult patients (age criteria varied, commonly 18–75)

These reflect eligibility across multiple device and procedure studies rather than a single uniform payer requirement.

Study-based patient selection elements

Common eligibility elements reported in randomized trials of TIF and MSA:

Trial-style selection elements: Persistent/regurgitative GERD despite optimized PPI therapy AND objective evidence of pathologic reflux by ambulatory pH testing AND limited hiatal hernia size (commonly ≤2–3 cm) AND absence of advanced esophagitis or Barrett's in some trials

These are study inclusion elements reported in the document and inform typical patient selection used in trials.

MSA (LINX) — evidence summary and patient selection

Evidence and typical selection considerations for MSA (LINX):

MSA evidence and selection: Patients considered for magnetic sphincter augmentation typically have objective pathologic acid reflux by pH testing and symptoms inadequately controlled by medical therapy; observational studies and systematic reviews report improvements in acid exposure, GERD‑HRQL scores, and PPI discontinuation but randomized comparative long-term data beyond 1 year are limited; specific factors (eg, BMI, defective LES, hiatal hernia) may affect outcomes

Supported by randomized trials and post-approval series; limitations include short follow-up and observational data predominance.

EndoFLIP — evidence limitations and current status

EndoFLIP (FLIP) utility and limitations:

EndoFLIP evidence: EndoFLIP has been evaluated for diagnosis and procedural guidance in achalasia, GERD, and other disorders, but current evidence is insufficient to establish standardized diagnostic thresholds or to demonstrate improved health outcomes; larger RCTs with long-term follow-up are needed

Systematic reviews and technology assessments find evidence inconclusive and lacking standardized DI thresholds.

Guidelines and professional society stances

Professional society recommendations relevant to coverage decisions:

Guideline positions: Major societies (ACG, AGA, ASGE, ASGS, SAGES) recognize MSA as an alternative to fundoplication in selected patients and recommend surgery for objective GERD; POEM is recommended as a primary or acceptable option for specified achalasia subtypes and by experienced operators; recommendations for Stretta and other endoscopic GERD therapies vary across societies

Society statements include conditional recommendations and emphasize operator expertise and patient selection.

POEM Coverage Distinctions

Covered when the following indication-specific conditions are met:

POEM - Covered Indications: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm.

Coverage distinction added in the Coverage Rationale summary dated 03/01/2025.

POEM - Not Covered Indications: POEM is unproven and not medically necessary for all other indications (for example, Zenker's diverticula) due to insufficient evidence of efficacy.

Coverage distinction added in the Coverage Rationale summary dated 03/01/2025.

POEM and related endoscopic myotomy approaches performed for indications other than Achalasia or Diffuse Esophageal Spasm (for example, treatment of Zenker's diverticulum / Z‑POEM) are considered unproven and not medically necessary due to insufficient quality evidence and limited long‑term data supporting safety and effectiveness.

Several procedures described in the document — including G‑POEM and other novel endoscopic myotomy variants — are characterized as innovative or experimental with insufficient high‑quality, long‑term evidence to generalize results; routine coverage is not supported without documentation of refractory disease, objective testing, and specialist expertise.

Applicability of study results to routine clinical practice is limited in certain populations: many trials excluded patients with severe esophagitis, lacked uniform objective reflux testing, or enrolled patients with well‑characterized PPI responsiveness. Absence of these objective data in a candidate restricts applicability of the published evidence.

The evidence base for transoral incisionless fundoplication (TIF) and magnetic sphincter augmentation (LINX/MSA) is limited by lack of long‑term randomized comparative data. Systematic reviews report short‑ to mid‑term improvements in selected outcomes, but uncertainty remains whether these approaches provide durable alternatives to laparoscopic Nissen fundoplication or continued medical therapy.

Multiple statements in the clinical literature and technology assessments emphasize caution because randomized long‑term comparative data are limited; reviewers and clinicians should not extrapolate short‑term trial results to long‑term effectiveness without confirmatory studies.

Regulatory clearance or FDA approval of a device or procedure is provided for informational context only; FDA approval alone is not a basis for coverage and does not supersede payer medical necessity determinations.

Per oral endoscopic myotomy (POEM) for indications other than Achalasia or Diffuse Esophageal Spasm (for example, Z‑POEM for Zenker's diverticulum) is currently unproven and not medically necessary because available studies are small, heterogeneous, and lack standardized long‑term outcome data.

G‑POEM for gastroparesis, endoluminal GERD therapies (including Stretta), and use of FLIP for diagnostic or routine procedural guidance are described in the policy as unproven or investigational for the specified indications due to insufficient high‑quality evidence and uncertain long‑term benefit.

There is a notable lack of high‑quality, long‑term randomized data for both POEM (comparisons versus laparoscopic Heller myotomy beyond one year) and Stretta (mixed randomized evidence with some sham‑controlled trials showing no effect). This evidence gap limits confidence in durability of benefit.

For many endoscopic therapies, long‑term effectiveness data are often lacking; several case series and long‑term follow‑up reports demonstrate symptom improvements that diminish over time, underscoring uncertainty about sustained benefit.

Polymer injection and implantation techniques (for example, Plexiglas, Durasphere and earlier endoscopic bulking agents) lack sufficient evidence from controlled trials to establish safety and long‑term efficacy, and therefore are not considered proven therapeutic options for routine GERD treatment.

EndoFLIP (FLIP) has been evaluated as an adjunctive tool for diagnosis and procedural guidance, but current evidence is insufficient to support routine use for diagnostic assessment, intra‑procedural decision‑making, or standard post‑procedure evaluation because diagnostic thresholds and impact on clinical outcomes remain undetermined.

POEM applied to non‑achalasia indications (including Zenker's diverticulum and other variants) remains unproven and is considered not medically necessary pending higher‑quality, long‑term comparative studies demonstrating clinically meaningful benefit.

Procedure and Device Coding

Prior Authorization

Provider Action/Authorization Requirements

Prior authorization is recommended for novel peroral endoscopic myotomy (POEM) procedures and other endoscopic antireflux/device-based GERD interventions. Authorization requires documentation that conservative therapy has been tried and failed, including an adequate trial of a proton pump inhibitor (PPI) at guideline-directed dosing. Authorization should include documentation of refractory GERD (symptoms despite medical therapy) and objective testing results (e.g., endoscopy, ambulatory pH or pH-impedance monitoring, esophageal manometry, and when available FLIP/EGJ distensibility measurements). Providers should reference contractual, federal, and state benefit terms; coverage is subject to member-specific benefits and applicable laws.

Denial Risk

Denial Risk / Documentation

Provider should include device-specific prior authorization notes when applicable (for example, LINX, EsophyX, Stretta, other FDA-cleared devices). Prior authorization may be denied for non–FDA-approved or non–cleared indications and for procedures lacking sufficient objective diagnostic evidence. Potential clinical reasons for noncoverage or further review include: lack of adequate PPI trial, absence of objective testing demonstrating pathologic reflux or suitable anatomic findings, procedural indication that is investigational or experimental, and failure to document prior conservative therapy (behavioral measures, weight loss, or optimization of reflux medications).

Prior Authorization, Documentation, and Operational Notes

Prior Authorization

Prior authorization required for POEM and related codes

Prior authorization is expected for POEM and related procedure codes; POEM (CPT 43497) is designated medically necessary for achalasia and diffuse esophageal spasm, while other esophageal/stomach unlisted codes may require prior authorization per payer rules.

POEM (CPT 43497) is proven and medically necessary for Achalasia or Diffuse Esophageal Spasm.
Other related or unlisted esophagus/stomach procedure codes may require prior authorization per plan rules.

Prior Authorization

Obtain prior authorization for novel POEM procedures (G-POEM, Z-POEM)

For novel POEM variants (for example, G-POEM or Z-POEM), prior authorization should be obtained and include documentation of refractory symptoms despite standard therapy and appropriate objective testing (e.g., gastric emptying study for G-POEM).

G-POEM is described as innovative with insufficient quality evidence; prior authorization should justify medical necessity.
Include objective testing (e.g., GES) and documentation of failed standard therapies.

Clinical Background and Definitions

Achalasia is a primary esophageal motor disorder characterized by degeneration of the myenteric plexus, impaired relaxation of the esophagogastric junction, and loss of organized peristalsis, typically presenting with progressive dysphagia and regurgitation.

Achalasia

DefinitionA primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, impaired relaxation of the esophagogastric junction, and loss of organized peristalsis.

Typical presentationDysphagia, regurgitation, and impaired esophageal emptying; diagnosis usually by manometry and clinical assessment.

Relevant therapyPeroral endoscopic myotomy (POEM) is described in the policy as a proven, medically necessary treatment for achalasia when criteria are met.

Diffuse Esophageal Spasm

Definition

Policy Changes and Revision Notes

2026-04-01retirementLatest

Policy retired for Louisiana membership effective 04/01/2026.

2025-03-01coverage_clarification

Coverage Rationale clarified that POEM is proven and medically necessary for Achalasia and Diffuse Esophageal Spasm and unproven/not medically necessary for all other indications (e.g., Zenker's diverticula).

This policy's conclusions incorporate published clinical evidence and technology assessments; the references list has been updated to include recent systematic reviews, randomized trials, and cohort studies that inform the coverage distinctions presented.

Policy Summary

PayerUnitedHealthcare

PolicyEndoscopic therapies for esophageal and gastric motility disorders (POEM, G-POEM, endoluminal GERD therapies)

Policy CodePolicy CS079LA.M

Change TypeClarified covered vs unproven indicationsreferences updatedpolicy retirement for LA

Effective DateMar 1, 2025

Next Review DateN/A

Key ActionSubmit prior authorization documenting diagnosis of Achalasia or Diffuse Esophageal Spasm and required objective testing when requesting POEM; other indications may be denied.

SourceLink

On This Page

Endoscopic therapies, injection/implantation techniques, and devices (including LINX Reflux Management System and GERDx ™) are considered unproven and not medically necessary for treating GERD absent sufficient evidence of efficacy or FDA-cleared/accepted indication consistent with coverage rules

Policy lists these approaches as unproven/not medically necessary for GERD.

Documentation Required

Coding Documentation and Suggested Supporting Records

Submit applicable procedure and diagnosis codes on the claim. Include operative reports, preoperative diagnostic testing (EGD reports, ambulatory pH/pH-impedance study results, high-resolution manometry), and any FLIP (EndoFLIP) measurements if performed. Suggested procedural documentation and follow-up data: detailed indication and symptoms, prior medical therapy and duration (including PPI dose and dates), objective test results with dates, device or technique used, intraoperative findings, complications, and post-procedure outcomes and follow-up testing. Reference contractual/federal/state benefit terms when interpreting coverage.

Reference CPT / Procedure CodesCPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty
43257	EGD with delivery of thermal energy to LES/gastric cardia
43284	Laparoscopy, esophageal sphincter augmentation device placement
43289	Unlisted laparoscopy procedure, esophagus
43497	Lower esophageal myotomy, transoral (POEM)
43499	Unlisted procedure, esophagus
43999	Unlisted procedure, stomach

Billing Rule

Coding documentation — providers should submit applicable procedure codes (e.g., 43497 for POEM)

Coding documentation — providers should submit applicable procedure codes (e.g., 43497 for POEM) with operative reports and the objective preoperative testing listed above. Include device model/identifier when a device-specific procedure is performed.

Prior Authorization

Prior authorization for endoscopic fundoplication/TIF — confirm PPI dependence/refractoriness

Prior authorization for endoscopic fundoplication/TIF should confirm the patient is PPI-dependent or refractory to PPI therapy and that objective confirmation of pathologic acid exposure is documented.

Trials generally enrolled patients dependent on or refractory to PPI therapy.
Objective evidence of pathologic acid exposure was required in device studies.

Prior Authorization

MSA prior authorization — document pathologic acid exposure and prior therapy

Prior authorization for magnetic sphincter augmentation (MSA/LINX) should document pathologic esophageal acid exposure by pH testing, prior medical management attempts, and assessment of anatomic factors that may affect outcome.

MSA studies required abnormal pH testing and prior PPI therapy.
Document hiatal hernia size, LES characterization, and prior medical management attempts.

Prior Authorization

Specify device and indication; device-specific documentation may be required

When seeking authorization for device-based procedures, specify the device and indication consistent with FDA-cleared or approved uses, as some devices listed in the policy (e.g., LINX, EsophyX2, MUSE, EndoFLIP, Stretta) may require device-specific documentation.

Device approvals/clearances are informational; provide device model and intended indication when relevant.
FDA approval alone is not a basis for coverage; align documentation with payer/device criteria.

Prior Authorization

Prior authorization must reflect POEM coverage distinctions (achalasia/ DES vs other indications)

Prior authorization for POEM should reflect coverage distinctions: POEM is considered medically necessary for achalasia and diffuse esophageal spasm, but POEM for other indications is unproven and not medically necessary and may be denied.

POEM (CPT 43497) — covered for Achalasia or Diffuse Esophageal Spasm.
POEM for other indications (e.g., Zenker's diverticula) is unproven and not medically necessary.

Step Therapy

Document conservative therapy trial before endoscopic interventions

Before endoscopic options are considered for GERD or related conditions, conservative therapies (OTC antacids, H2RAs, PPIs) and established surgical options such as Nissen fundoplication should be documented as tried or considered.

Initial GERD treatment typically includes OTC antacids, H2RAs, and PPI therapy.
Document trials of medical therapy and consideration of surgical options where applicable.

Step Therapy

Document prior failure of medical therapy for G-POEM candidates

For G-POEM candidates, prior failure of medical therapy and dietary measures is expected; studies enrolled patients with refractory gastroparesis after failure of conservative and prokinetic treatments for ≥6 months.

G-POEM trial eligibility commonly required symptom duration >6 months and failure of dietary modification and prokinetic/medical therapy.
Include GCSI and GES results when available to support refractory status.

Step Therapy

Document inadequate response to or dependence on PPI therapy

Authorization for endoscopic antireflux procedures typically expects documentation of an inadequate response to, or dependence on, PPI therapy prior to intervention.

Trials and guideline discussions describe PPI dependence or refractoriness as an enrollment criterion.
Document duration and dose of prior PPI therapy where relevant.

Step Therapy

Confirm prior adequate PPI trial (including escalated/double-dose when applicable)

Confirm and document that an adequate PPI trial was attempted; clinical trials compared procedures to continued or escalated PPI therapy (including double-dose PPI), so prior adequate medical therapy should be evident in the record.

Some RCTs required daily PPI use for specified durations and compared interventions to double-dose PPI.
Record prior PPI regimen, duration, and response to support medical necessity.

Step Therapy

Consider antireflux surgery after objective GERD evidence and failed medical therapy

Consider sequencing to antireflux surgery after objective evidence of GERD and failed medical therapy; guidelines recommend surgery (including MSA) for patients with objective reflux and persistent symptoms despite medical management.

Guidelines recommend antireflux surgery for patients with objective evidence of GERD who fail medical therapy.
TIF may be considered for selected patients who decline surgery and do not have severe esophagitis or large hiatal hernia.

Documentation Required

Provider actions — submit complete clinical and device documentation to support requests

Providers should document clinical details that support medical necessity, such as indication, prior therapies tried, objective testing results, device model (if applicable), and specialist training/experience for procedures like POEM.

Include diagnosis (e.g., Achalasia, Diffuse Esophageal Spasm), prior medical therapy, objective testing (pH, GES), and provider expertise.
When devices are used, specify device and FDA-cleared indication if applicable.

Note

Be aware UnitedHealthcare may apply external UM tools (e.g., InterQual)

UnitedHealthcare may use external utilization management tools (for example, InterQual) to assist in administering benefits and coverage decisions; include required documentation consistent with such tools when applicable.

Check whether plan-specific external criteria (e.g., InterQual) apply to the request.
Provide documentation aligned with external tool requirements if used by the payer.

Documentation Required

Include procedural details and follow-up data (GCSI, GES, QoL indices) for G-POEM

For G-POEM cases and associated studies, include suggested procedural and follow-up data elements such as GCSI scores, gastric emptying study results, and quality-of-life indices with follow-up visits at defined intervals to demonstrate clinical response.

Pre-procedural GCSI, GIQLI and GES are commonly reported in studies.
Follow-up often at 1, 3, 6 months and then every 6 months thereafter.

Documentation Required

Pre-procedure documentation — chronic GERD symptoms, prior PPI therapy, and objective testing

Typical pre-procedure documentation for endoluminal GERD or MSA procedures should include chronic GERD symptom documentation, prior PPI therapy (often >6 months or PPI dependence), and objective testing such as pathologic esophageal acid exposure or DeMeester score.

Document symptom history, duration and response to PPI therapy.
Provide objective test results (pH monitoring, DeMeester score) and hiatal hernia assessment.

Documentation Required

Include GERD-HRQL, endoscopy, barium, pH monitoring, manometry in preop documentation

Preoperative diagnostics commonly reported in MSA studies include validated symptom questionnaires (GERD-HRQL), upper endoscopy, barium swallow, ambulatory esophageal pH monitoring, and esophageal manometry; include these studies when available to support authorization.

GERD-HRQL scores, EGD findings, barium swallow, pH monitoring, and manometry were part of MSA preoperative assessment.
Provide these results to substantiate objective reflux and anatomic suitability.

Documentation Required

Documentation elements to support MSA (objective reflux evidence, prior therapy, anatomy, BMI, consent)

Documentation to support MSA should include objective evidence of pathologic acid reflux (esophageal pH testing), prior medical therapy response, anatomical assessment of LES and hiatal hernia, BMI, and informed consent acknowledging risks such as device erosion and possible removal.

Provide pH testing results, prior therapy history, hiatal hernia size, and BMI.
Document informed consent addressing device-specific risks including erosion and removal.

Documentation Required

If device used, document FDA device identifier and indication (PMA/510(k))

PMA approvals and 510(k) clearances for specific devices are listed in the policy and may necessitate documentation of device model and indication when seeking coverage for device-based procedures.

Examples: LINX PMA P100049, EsophyX2 510(k), EndoFLIP 510(k).
When device-specific criteria apply, include device identification and intended use in the request.

Note

Reference applicable federal, state, or contractual benefit terms

Reviewers must reference federal, state, or contractual benefit plan requirements when deciding coverage; this policy is informational and supplemental to governing benefit documents.

In the event of conflict, federal/state/contractual terms govern coverage decisions.
Confirm plan-specific coverage rules before submitting an authorization request.

Denial Risk

Denial risk: POEM for non-approved indications (e.g., Zenker's)

Requests for POEM performed for indications other than achalasia or diffuse esophageal spasm (for example, POEM for Zenker's diverticula) may be denied as unproven and not medically necessary.

Policy explicitly states POEM is unproven and not medically necessary for other indications.
Provide strong justification and supporting evidence if requesting POEM for non-covered indications.

Denial Risk

Denial risk: inadequate evidence for G-POEM may lead to denial

Insufficient high-quality evidence and lack of long-term effectiveness data for G-POEM may prompt denial or requests for additional documentation to justify medical necessity.

G-POEM is described as innovative with insufficient quality evidence and variable follow-up.
Authorization may require rigorous documentation of refractory disease and objective testing.

Denial Risk

Documentation risk: missing abnormal acid exposure or prior PPI history may prompt denial

Failure to document objective abnormal esophageal acid exposure, prior PPI use, or appropriate patient selection may lead to coverage denial; studies note variability in selection and emphasize documented abnormal testing and prior therapy.

Lack of documented abnormal pH testing or prior PPI trials can undermine authorization requests.
Ensure objective testing and prior treatment history are included to reduce documentation risk.

Denial Risk

Denial risk: long-term evidence gaps for LINX/MSA may affect coverage

Insufficient long-term safety and efficacy evidence for LINX/MSA may lead to denial or requests for additional documentation; the policy notes limited long-term data despite promising short-term results.

MSA studies report positive short-term outcomes but limited long-term comparative data.
Provide long-term follow-up data where available to support medical necessity.

Denial Risk

Potential noncoverage reasons: high BMI or defective LES may preclude MSA

Clinical factors such as high BMI, structurally defective LES, or other anatomic issues cited in studies may make patients poor candidates for MSA and can lead to noncoverage or further review.

Studies identified BMI >35 and structurally defective LES as negative predictors of good outcome.
Document anatomical assessments and BMI to demonstrate suitability.

Note

FDA approval alone does not guarantee coverage

Note that FDA approval or clearance of a device is informational only and does not, by itself, guarantee coverage; coverage decisions may still deny services based on payer policy.

Policy states FDA approval alone is not a basis for coverage.
Align requests with plan-specific coverage criteria in addition to device approvals.

Denial Risk

Denial risk: POEM for non-covered indications reiterated (policy revision note)

Procedures performed for indications other than achalasia or diffuse esophageal spasm (for example, POEM for Zenker's diverticula) are considered unproven and not medically necessary and may be denied.

Policy revision clarifies POEM is proven only for Achalasia and Diffuse Esophageal Spasm (03/01/2025).
Non-approved POEM indications should be supported by strong evidence to avoid denial.

Note

Background: Coverage distinctions for POEM and related therapies (informational)

This background note summarizes clinical context for providers: POEM is proven for achalasia and diffuse esophageal spasm, while other POEM variants and many endoluminal GERD therapies are considered investigational or unproven.

G-POEM is unproven for gastroparesis; FLIP is unproven for diagnosing achalasia; several GERD endoluminal therapies are unproven for routine use.
Refer to the policy Coverage Rationale for indication-specific coverage stances.

Note

Use of external utilization management tools (e.g., InterQual)

UnitedHealthcare may use external tools such as InterQual to assist in administering benefits and coverage decisions; align submitted documentation with any external criteria the plan applies.

Check whether InterQual or other third-party criteria are being applied to the authorization.
Provide documentation consistent with such criteria to facilitate review.

A rare esophageal motility disorder characterized by simultaneous, uncoordinated, or rapidly propagated contractions of normal amplitude accompanied by dysphagia.

DiagnosisClinical assessment and manometry are used; may be considered for POEM when presentation matches diffuse spasm criteria.

Coverage notePOEM is considered proven and medically necessary for Diffuse Esophageal Spasm when policy criteria are met.

Gastroesophageal Reflux Disease (GERD)

DefinitionA condition in which the lower esophageal sphincter relaxes too often or weakens, allowing stomach acid to reflux into the esophagus.

Typical managementInitial therapy is medical (PPIs, H2RAs, antacids); endoscopic or surgical options are considered for refractory disease with objective testing.

Objective testingTrials commonly required objective confirmation of pathologic esophageal acid exposure (e.g., pH monitoring/DeMeester score) prior to endoscopic interventions.

Gastroparesis

DefinitionA chronic disorder characterized by delayed gastric emptying without mechanical obstruction.

Clinical contextSymptoms include nausea, vomiting, early satiety; assessment often includes gastric emptying study (GES) and GCSI symptom scoring in trials.

Coverage noteG-POEM for gastroparesis is considered unproven and not medically necessary by this policy due to insufficient quality evidence.

POEM (Peroral Endoscopic Myotomy)

DefinitionPeroral endoscopic myotomy (POEM) — an endoscopic technique that creates a submucosal tunnel to perform esophageal myotomy, cutting muscle fibers to relieve outflow obstruction at the lower esophageal sphincter.

IndicationsPolicy notes POEM is proven and medically necessary for Achalasia and Diffuse Esophageal Spasm when criteria are met.

Evidence summarySystematic reviews and randomized trials compare POEM to laparoscopic Heller myotomy, showing comparable short- to intermediate-term outcomes but limited long-term data beyond one year.

Z-POEM (Zenker's POEM)

DefinitionZ-POEM — peroral endoscopic myotomy applied to Zenker's diverticulum involving endoscopic septotomy/myotomy of the diverticular septum.

OutcomesCohort studies report high initial clinical success rates but variable recurrence and adverse event profiles; long-term comparative data are limited.

Policy stancePOEM for indications other than achalasia (including Z-POEM) is considered unproven and not medically necessary due to insufficient evidence.

G-POEM (Gastric POEM)

DefinitionG-POEM — gastric peroral endoscopic myotomy (endoscopic pyloromyotomy) intended to improve gastric emptying in refractory gastroparesis.

Evidence summaryCurrent literature is insufficient in quality and generalizability; trials show heterogenous outcomes and further study is needed to identify responsive subgroups.

Coverage stanceG-POEM is stated as unproven and not medically necessary for gastroparesis in this policy.

Stretta (Radiofrequency therapy)

DefinitionStretta — endoscopic delivery of radiofrequency energy to the gastroesophageal junction intended to reduce GERD symptoms.

Evidence balanceRandomized and observational studies show mixed results; meta-analyses suggest symptom improvement but overall quality of evidence is low and uncertainty remains compared with surgical fundoplication.

Recommendation contextFurther robust, long-term randomized trials are needed to define Stretta's role in GERD management.

DeMeester score / Esophageal acid exposure

DefinitionDeMeester score / esophageal acid exposure — objective measures from ambulatory pH monitoring quantifying percent time pH <4 used to assess pathologic reflux.

Use in studiesSeveral device and procedure studies required abnormal esophageal acid exposure or elevated DeMeester scores as inclusion criteria and measured change post-procedure.

Clinical relevanceNormalization or reduction in percent time pH <4 and DeMeester scores is a common objective endpoint in GERD trials.

Clinical success (as used in studies)

DefinitionClinical success — in many studies defined as ≥50% improvement in GERD-HRQL total score combined with discontinuation of PPI medication; other studies used elimination of troublesome regurgitation or symptom remission at pre-defined follow-up.

VariabilityDefinitions vary across studies and may include symptom score thresholds, PPI cessation, or disease-specific questionnaire improvements, affecting comparability of results.

ImplicationWhen assessing outcomes, confirm the specific success criteria used in each study as they differ between trials and cohorts.

Magnetic Sphincter Augmentation (MSA/LINX)

DefinitionMagnetic sphincter augmentation (MSA/LINX) — a surgically implanted ring of magnetic beads placed around the gastroesophageal junction to augment the lower esophageal sphincter and reduce pathologic reflux.

Regulatory noteThe LINX Reflux Management System received FDA premarket approval (PMA P100049).

Clinical outcomesStudies report improvements in acid exposure, GERD-HRQL scores, and high rates of PPI discontinuation, with device removal/erosion reported in a minority of patients.

EndoFLIP (Functional Lumen Imaging Probe)

DefinitionEndoFLIP (Functional Lumen Imaging Probe) — an intra-luminal impedance planimetry system that measures distensibility and cross-sectional area of sphincters (eg, the esophagogastric junction) to assess pressure and dimensions during endoscopy.

Intended useThe device is indicated as an adjunct to other diagnostic methods to evaluate patients with symptoms consistent with gastrointestinal motility disorders (510(k) cleared).

LimitationsEvidence is insufficient to establish diagnostic thresholds or to show improved health outcomes; standardized protocols and validated cutpoints (eg, DI thresholds) are lacking.

EndoFLIP — device regulatory description

Regulatory descriptionEndoFLIP is an impedance planimetry system indicated to measure pressure and dimensions in the esophagus, pylorus, and anal sphincters and received 510(k) approval on April 17, 2017; intended as an adjunct to other diagnostic methods.

Device classClass II device (moderate risk) deemed substantially equivalent to other endoscopic devices as noted in FDA materials.

Clinical roleUsed to augment diagnostic evaluation and procedural guidance, but policy states evidence is insufficient to support routine use for diagnostic decision-making.

LINX Reflux Management System (PMA P100049)

DeviceLINX Reflux Management System — a magnetic sphincter augmentation device for GERD that received FDA premarket approval (PMA P100049).

Regulatory referencePMA number referenced: P100049 (see FDA PMA database for details).

NoteFDA approval is informational; this policy states that FDA approval alone is not a basis for coverage decisions.

POEM for achalasia or diffuse esophageal spasm (coverage definition)

Definition — covered usePOEM for achalasia or diffuse esophageal spasm: proven and medically necessary when policy criteria are satisfied.

Supporting evidencePolicy revision (03/01/2025) clarified POEM coverage distinctions; randomized trials and systematic reviews provide the evidence base for achalasia indications.

Scope limitationPOEM coverage is limited to achalasia and diffuse esophageal spasm; other indications are unproven and not medically necessary.

POEM for other indications (unproven/not medically necessary)

Definition — non-covered usesPOEM for other indications (e.g., Zenker's diverticula/Z-POEM, G-POEM for gastroparesis) is considered unproven and not medically necessary due to insufficient evidence of efficacy and long-term outcomes.

ExamplesZ-POEM and G-POEM are specifically noted as innovative/novel with limited high-quality long-term data; therefore routine coverage is not supported.

RecommendationRequests for POEM for non-approved indications may be denied as unproven; prior authorization should document refractory disease and objective testing when considered.